Natera, Inc. (NTRA) News
Filter NTRA News Items
NTRA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
NTRA News Highlights
- For NTRA, its 30 day story count is now at 31.
- Over the past 23 days, the trend for NTRA's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- AP, DNA and ACT are the most mentioned tickers in articles about NTRA.
Latest NTRA News From Around the Web
Below are the latest news stories about Natera Inc that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera: Q4 Earnings SnapshotAUSTIN, Texas (AP) _ Natera Inc. (NTRA) on Thursday reported a loss of $140.6 million in its fourth quarter. The Austin, Texas-based company said it had a loss of $1.48 per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share. The genetic testing company posted revenue of $173 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $168.2 million. For the year, the company reported that its loss widened to $471.7 million, or $5.21 per share. Revenue was reported as $625.5 million. Natera expects full-year revenue in the range of $770 million to $790 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/... |
Natera, Inc. 2021 Q4 - Results - Earnings Call PresentationNo summary available. |
Natera GAAP EPS of -$1.48 misses by $0.18, revenue of $173M beats by $4.19MNatera press release (NTRA): Q4 GAAP EPS of -$1.48 misses by $0.18.Revenue of $173M (+53.9% Y/Y) beats by $4.19M.Outlook:Natera anticipates 2022 total revenue of $770 million to… |
Natera (NTRA) Reports Q4 Loss, Tops Revenue EstimatesNatera (NTRA) delivered earnings and revenue surprises of -19.35% and 2.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Natera Reports Fourth Quarter and Full Year 2021 Financial ResultsNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on recent business progress and financial outlook. |
Natera Q4 2021 Earnings Preview (NASDAQ:NTRA)Natera (NASDAQ:NTRA) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$1.31 (-47.2% Y/Y) and the consensus… |
Natera''s Debt OverviewOver the past three months, shares of Natera (NASDAQ: NTRA ) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has. Check out this: Insiders Buy More Than $170M Of 4 Stocks Natera''s Debt According to the Natera''s most recent balance sheet as reported on November 5, 2021, total debt is at $330.13 million, with $280.08 million in long-term debt and $50.05 million in current debt. Adjusting for $95.10 million in cash-equivalents, the company has a net debt of $235.03 million. Let''s define some of the terms we used in the paragraph above. Current debt is the portion of a company''s debt which Full story available on Benzinga.com |
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue EstimatesTeladoc (TDOC) delivered earnings and revenue surprises of 88.14% and 1.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference CallNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2021, after the market close on February 24, 2022. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook. |
Analysts Estimate Natera (NTRA) to Report a Decline in Earnings: What to Look Out forNatera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |